Burning Rock Biotech

BNRPhase 2

Burning Rock Biotech is a publicly-traded, commercial-stage diagnostics company specializing in precision oncology. Its core mission is to transform cancer treatment through early detection and personalized therapy selection using advanced genomic profiling. The company has established a significant commercial footprint in China with its portfolio of NGS-based in-vitro diagnostic (IVD) products and laboratory-developed tests (LDTs), while actively developing its multi-cancer early detection (MCED) pipeline. Its strategic direction involves expanding its product portfolio, pursuing regulatory approvals, and exploring international markets.

Market Cap

$172.7M

Employees

500-1000

Focus

Biotech

BNR · Stock Price

USD 19.1275.18 (-79.72%)

Historical price data

AI Company Overview

Technology Platform

A proprietary, high-throughput next-generation sequencing (NGS) platform optimized for clinical oncology, integrating specialized wet-lab workflows for tissue and liquid biopsy with advanced bioinformatics pipelines for comprehensive genomic profiling and methylation analysis.

Pipeline Snapshot

1 drug in pipeline

Drug	Indication	Stage	Watch
Furmonertinib	Adenocarcinoma of Lung	Phase 1/2

Funding History

Total raised: $150M

IPOUndisclosedUndisclosedJun 15, 2020

Series B$100MGICJun 15, 2017

Series A$50MSequoia Capital ChinaJun 15, 2015

Opportunities

The massive, underpenetrated market for multi-cancer early detection in China's aging population represents a transformative long-term opportunity.

Additionally, the growing adoption of targeted and immuno-oncology therapies continues to drive demand for its core therapy selection tests, with potential for expansion into companion diagnostic co-development with global pharma partners.

Risk Factors

Key risks include evolving and uncertain LDT regulations in China, potential pricing pressure and reimbursement challenges for its diagnostic tests, the high cost and clinical validation risk associated with its MCED pipeline, and geopolitical tensions affecting its U.S.

listing status.

Competitive Landscape

Burning Rock faces intense competition from domestic NGS leaders like Genetron Health and Berry Oncology in therapy selection, and from global players like Grail and Exact Sciences in early detection. Its differentiation lies in its first-mover NMPA approvals, established hospital network in China, and proprietary methylation technology for its MCED program.